1 Siegel HJ,Pressey JG.Current concepts on the surgical and medical management of osteosarcoma[J].Expert Rev Anticancer Ther,2008,8(8):1257-1269. 2 Doble BW,Woodgett JR.GSK3:tricks of the trade for a multi-tasking kinase[J].J Cell Sci,2003,116(7):1175-1186. 3 Jee SH,Ohrr H,Sull JW,et al.Fasting serum glucose level and cancer risk in Korean men and women[J].JAMA,2005,293(2):194-202. 4 Cohen P,Goedert M.GSK3 inhibitors:development and therapeutic potential[J].Nat Rev Drug Discov,2004,3(6):479-487. 5 King MR,Anderson NJ,Guernsey LS,et al.Glycogen synthase kinase-3 inhibition prevents learning deficits in diabetic mice[J].J Neurosci Res,2013,91(4):506-514. 6 Miyashita K,Kawakami K,Nakada M,et al.Potential therapeutic effect of glycogen synthase kinase 3β inhibition against human glioblastoma[J].Clin Cancer Res,2009,15(3):887-897. 7 Wang Z,Smith KS,Murphy M,et al.Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy[J].Nature,2008,455(7217):1205-1209. 8 Kunnimalaiyaan M,Vaccaro AM,Ndiaye MA,et al.Inactivation of glycogen synthase kinase-3beta,a downstream target of the raf-1 pathway,is associated with growth suppression in medullary thyroid cancer cells[J].Mol Cancer Ther,2007,6(3):1151-1158. 9 Smalley KS,Contractor R,Haass NK,et al.An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells[J].Cancer Res,2007,67(1):209-217. 10 Cai YP,Mohseny AB,Karperien M,et al.Inactive Wnt/β-catenin pathway in conventional high-grade osteosarcoma[J].J Pathol,2010,220(1):24-33. 11 Tang QL,Xie XB,Wang J,et al.Glycogen synthase kinase-3,NF-κB signaling,and tumorigenesis of human osteosarcoma[J].J Natl Cancer Inst,2012,104(10):749-763. |